Reactions Weekly

, Volume 1673, Issue 1, pp 282–282 | Cite as

Nivolumab/pembrolizumab

Bullous pemphigoid and bullous eruption: 3 case reports
Case report
  • 21 Downloads

Reference

  1. Edwards C, et al. A case series of immunotherapy-induced blistering skin disease occurring in association with nivolumab [an antiprogrammed cell death (PD)-1 monoclonal antibody] and pembrolizumab (an anti-PD-ligand 1 monoclonal antibody). British Journal of Dermatology 177 (Suppl. 1): 24 abstr. CPC 14, Jul 2017. Available from: URL: http://doi.org/10.1111/bjd.15428 [abstract] - UnitedKingdom

Copyright information

© Springer International Publishing AG 2017

Personalised recommendations